Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2016 01:37 ET | Source: MorphoSys AG

MorphoSys Initiates Phase 2 Combination Trial of MOR208 and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

MARTINSRIED / MUNICH, Germany, April 6, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient was dosed in a phase 2...
April 04, 2016 11:48 ET | Source: MorphoSys AG

Ad hoc: MorphoSys Sues Janssen Biotech and Genmab for Patent Infringement

MARTINSRIED / MUNICH, Germany, April 4, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that it filed a lawsuit in the United States (U.S.)...
March 02, 2016 01:04 ET | Source: MorphoSys AG

MorphoSys AG Reports Results for Fiscal Year 2015

MARTINSRIED / MUNICH, Germany, March 2, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced financial results for the year ending December 31,...
February 25, 2016 04:08 ET | Source: MorphoSys AG

Invitation to Year End 2015 Conference Call of MorphoSys AG on March 2, 2016

MARTINSRIED / MUNICH, Germany, Feb. 25, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its Annual Financial Results 2015 on March 2, 2016 at 7:00 a.m....
February 24, 2016 11:02 ET | Source: MorphoSys AG

MorphoSys Announces Share Buy-Back Program

MARTINSRIED / MUNICH, Germany, Feb. 24, 2016 (GLOBE NEWSWIRE) -- The Management Board of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced with the approval of the...
January 26, 2016 01:35 ET | Source: MorphoSys AG

MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial Designed to Support Registration of Anetumab Ravtansine

MARTINSRIED / MUNICH, Germany, Jan. 26, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced that the company earned a milestone payment with...
January 07, 2016 10:45 ET | Source: MorphoSys AG

MorphoSys to Present at J.P. Morgan Healthcare Conference

MARTINSRIED / MUNICH, Germany, Jan. 7, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the upcoming J.P. Morgan Healthcare Conference in...
December 07, 2015 01:36 ET | Source: MorphoSys AG

MorphoSys Presents Interim Safety, Pharmacokinetic and Efficacy Data for MOR202 in Multiple Myeloma at ASH Meeting

MOR202 produced encouraging response rates as single agent and in first combination cohorts with immunomodulatory drugs (IMiDs). MOR202 is well tolerated and can be safely administered as a...
December 07, 2015 01:34 ET | Source: MorphoSys AG

New Clinical Data on MorphoSys's Blood Cancer Drug Candidate MOR208 in NHL and CLL Presented at ASH Annual Meeting

MARTINSRIED / MUNICH, Germany, Dec. 7, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced clinical data on its proprietary drug candidate...
November 16, 2015 08:10 ET | Source: MorphoSys AG

MorphoSys to Present at Two Upcoming Conferences

MARTINSRIED and MUNICH, Germany, Nov. 16, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: Jefferies Autumn...